Enlivex Ltd. (ENLV)Healthcare | Biotechnology | Ness Ziona, Israel | NasdaqCM
6.67 USD
-0.19
(-2.770%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 6.67 |
Hot Take ↕ | July 11, 2026, 7:04 a.m. EDT
The investment case for Enlivex is currently broken by a catastrophic lack of liquidity and severe structural damage. The company recently executed a 1-for-15 reverse stock split, a desperate measure often taken by distressed biotech firms to meet listing requirements, which has effectively erased the stock's liquidity and made standard trading nearly impossible. Fundamentally, the business is in freefall; despite a nonsensical headline claiming $1.23 billion in net income driven by treasury assets, the company is burning through cash at an alarming rate with operating cash flow of -$10 million and massive negative free cash flow. The balance sheet is fragile, with nearly $64 million in debt against only $5.7 million in cash, forcing the company to rely on dilutive capital raises. The market has correctly priced this reality, driving the stock down roughly 78% over the last year and leaving it trading at a fraction of its book value. With no analyst coverage, a reverse split looming, and a statistical model predicting further downside, there is no rational entry point for a short-term trader or a long-term holder until the company demonstrates a viable path to profitability without further dilution. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.113445 |
| AutoARIMA | 0.214450 |
| AutoETS | 0.217686 |
| MSTL | 0.245557 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 7.62 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.992 |
| Excess Kurtosis | 0.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.033 |
| Market Cap | 112,269,552 |
| Trailing P/E | 0.02 |
| Forward P/E | -8.55 |
| Beta | 1.52 |
| Previous Name | Enlivex Therapeutics Ltd. |
| Website | https://www.enlivex.com |
As of July 11, 2026, 7:04 a.m. EDT: Speculators are positioning for a significant downside move, evidenced by heavy out-of-the-money put volume and open interest concentrated at strikes well below the current price ($1.0 and $2.5), while call activity is negligible and focused only at the money. Implied volatility is elevated for these protective puts, suggesting a fear of a sharp decline rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6427083 |
| Address1 | 14 Einstein Street |
| All Time High | 6,600.0 |
| All Time Low | 6.42 |
| Ask | 8.48 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 48,975 |
| Average Daily Volume3 Month | 30,742 |
| Average Volume | 30,742 |
| Average Volume10Days | 48,975 |
| Beta | 1.516 |
| Bid | 5.06 |
| Bid Size | 2 |
| Book Value | 8.151 |
| City | Ness Ziona |
| Compensation As Of Epoch Date | 1,577,750,400 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.67 |
| Current Ratio | 193.236 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 7.4376 |
| Day Low | 6.86 |
| Debt To Equity | 0.033 |
| Display Name | Enlivex |
| Dividend Date | 1,551,830,400 |
| Earnings Timestamp End | 1,725,048,000 |
| Earnings Timestamp Start | 1,725,048,000 |
| Ebitda | -14,668,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.848 |
| Enterprise Value | 100,441,688 |
| Eps Forward | -0.78 |
| Eps Trailing Twelve Months | 382.2 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 10.3403 |
| Fifty Day Average Change | -3.6702995 |
| Fifty Day Average Change Percent | -0.354951 |
| Fifty Two Week Change Percent | -64.27083 |
| Fifty Two Week High | 31.5 |
| Fifty Two Week High Change | -24.83 |
| Fifty Two Week High Change Percent | -0.78825396 |
| Fifty Two Week Low | 6.42 |
| Fifty Two Week Low Change | 0.25 |
| Fifty Two Week Low Change Percent | 0.03894081 |
| Fifty Two Week Range | 6.42 - 31.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,406,813,400,000 |
| Float Shares | 3,847,798 |
| Forward Eps | -0.78 |
| Forward P E | -8.551283 |
| Free Cashflow | -1,737,054,976 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 34 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.81403 |
| Held Percent Institutions | 0.01441 |
| Implied Shares Outstanding | 16,832,015 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,783,555,200 |
| Last Split Factor | 1:15 |
| Long Business Summary | Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel. |
| Long Name | Enlivex Ltd. |
| Market | us_market |
| Market Cap | 112,269,552 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_84011067 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | 1,235,527,936 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 115,467,622 |
| Number Of Analyst Opinions | 1 |
| Open | 7.34 |
| Operating Cashflow | -10,416,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 972 2 620 8072 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 6.67 |
| Post Market Time | 1,783,979,577 |
| Prev Name | Enlivex Therapeutics Ltd. |
| Previous Close | 6.86 |
| Price Hint | 2 |
| Price To Book | 0.81830454 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.694 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.19 |
| Regular Market Change Percent | -2.76968 |
| Regular Market Day High | 7.4376 |
| Regular Market Day Low | 6.86 |
| Regular Market Day Range | 6.86 - 7.4376 |
| Regular Market Open | 7.34 |
| Regular Market Previous Close | 6.86 |
| Regular Market Price | 6.67 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 99,367 |
| Return On Assets | -0.00796 |
| Return On Equity | 1.26168 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 16,832,015 |
| Shares Percent Shares Out | 0.0063 |
| Shares Short | 100,757 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 27,851 |
| Short Name | Enlivex Ltd. |
| Short Percent Of Float | 0.0063 |
| Short Ratio | 3.96 |
| Source Interval | 15 |
| Symbol | ENLV |
| Target High Price | 299.99985 |
| Target Low Price | 299.99985 |
| Target Mean Price | 299.99985 |
| Target Median Price | 299.99985 |
| Total Cash | 5,755,000 |
| Total Cash Per Share | 0.364 |
| Total Debt | 641,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 382.2 |
| Trailing P E | 0.017451596 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 13.911125 |
| Two Hundred Day Average Change | -7.241125 |
| Two Hundred Day Average Change Percent | -0.52052766 |
| Type Disp | Equity |
| Volume | 99,367 |
| Website | https://www.enlivex.com |
| Zip | 7,403,618 |